THE WOODLANDS, Texas, June 15, 2011 /PRNewswire/ — Two clinical
trial studies authored by physicians affiliated with
US Oncology Research and the
United Network of US Oncology have been selected to be featured
in the Best of ASCO to be held July
29-30 in Miami and August 5-6 in Seattle.
The American Society of Clinical Oncology (ASCO) hosted its
47th Annual Meeting June 3-7 at McCormick Place in Chicago. The
Best of ASCO Meetings highlight the most relevant studies from the
ASCO Annual Meeting, which is the premier educational and
scientific event in the oncology community. This major medical
meeting highlights the most advanced treatments in cancer care and
attracts more than 26,000 cancer specialists from around the world.
This year’s annual meeting featured clinical trial studies that
include contributions from more than 70 clinical investigators
affiliated with McKesson Specialty Care
Solutions | US Oncology, a
division of McKesson Corporation focused on
empowering the community patient care delivery system to advance
the science, technology and quality of care.
Investigators affiliated with McKesson Specialty Care Solutions
| US Oncology contributed to more than 60 studies that were
presented at the ASCO Annual Meeting, including the two US Oncology
Research affiliated physicians listed below which have been chosen
to be featured in the Best of ASCO:
– Abstract #506: Correlation of molecular effects and pathologic
complete response to preoperative lapatinib and trastuzumab,
separately and combined prior to neoadjuvant breast cancer
chemotherapy. (
